全文获取类型
收费全文 | 193618篇 |
免费 | 2487篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 1300篇 |
儿科学 | 7243篇 |
妇产科学 | 3537篇 |
基础医学 | 19045篇 |
口腔科学 | 1783篇 |
临床医学 | 14630篇 |
内科学 | 34135篇 |
皮肤病学 | 999篇 |
神经病学 | 18294篇 |
特种医学 | 9458篇 |
外国民族医学 | 5篇 |
外科学 | 30719篇 |
综合类 | 2460篇 |
一般理论 | 18篇 |
预防医学 | 20366篇 |
眼科学 | 3014篇 |
药学 | 10693篇 |
中国医学 | 638篇 |
肿瘤学 | 17819篇 |
出版年
2023年 | 217篇 |
2022年 | 384篇 |
2021年 | 889篇 |
2020年 | 469篇 |
2019年 | 837篇 |
2018年 | 22672篇 |
2017年 | 17875篇 |
2016年 | 20064篇 |
2015年 | 1628篇 |
2014年 | 1754篇 |
2013年 | 1895篇 |
2012年 | 8622篇 |
2011年 | 22584篇 |
2010年 | 19586篇 |
2009年 | 12187篇 |
2008年 | 20588篇 |
2007年 | 22779篇 |
2006年 | 1574篇 |
2005年 | 3121篇 |
2004年 | 4224篇 |
2003年 | 5028篇 |
2002年 | 3092篇 |
2001年 | 361篇 |
2000年 | 512篇 |
1999年 | 262篇 |
1998年 | 338篇 |
1997年 | 301篇 |
1996年 | 168篇 |
1995年 | 161篇 |
1994年 | 157篇 |
1993年 | 108篇 |
1992年 | 96篇 |
1991年 | 134篇 |
1990年 | 154篇 |
1989年 | 124篇 |
1988年 | 101篇 |
1987年 | 85篇 |
1986年 | 63篇 |
1985年 | 65篇 |
1984年 | 62篇 |
1983年 | 48篇 |
1982年 | 46篇 |
1980年 | 63篇 |
1979年 | 33篇 |
1974年 | 34篇 |
1969年 | 31篇 |
1938年 | 60篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
961.
Objective To explore the relationship between expression of apoptosis-modulating proteins and histopathological grade and recurrence
in meningioma.
Methods Immunohistochemistry method (LSAB) was used to detect the expression of Bcl-2, Bax Bnd Bcl-XL in 80 cases of meningioma including benign group (38 cases), atypical group (26 cases) and malignant group (16 cases).
Results Expression of Bcl-2 oncoprotein positive in 88% cases in malignant group was significantly higher than that of benign group
(37%,P<0.05). There was no significant difference in the expression positive rate of Bax, Bcl-XL oncoprotein among benign, atypical and maligant groups (P>0.05), but Bcl-2+Bcl-XL/Bax was associated statistically with meningioma grade (P<0.01). There was no significant difference in the compare expression of Bcl-2, Bax, Bcl-XL oncoprotein positive in non-recurrent, initially resected recurrent and recurrent meningiomas (P>0.05).
Conclusion Bcl-2, Bax and Bcl-XL might play important roles in meningiomas and BCL-2+BCL-XL/Bax is useful parameters for estimation of biological behavior of meningiomas. 相似文献
962.
Nobuyuki Hamajima Atsuko Shibata Nobuyuki Katsuda Keitaro Matsuo Hidemi Ito Toshiko Saito Kazuo Tajima Suketami Tominaga 《Gastric cancer》2003,6(4):230-236
Background A possible association between Helicobacter pylori seropositivity and tumor necrosis factor (TNF) A G-308A has been reported in Korea. The present study examined the associations of H. pylori with functional polymorphisms, TNF-A G-308A, C-857T, and T-1031C, and TNF-B A252G in Japanese subjects.Methods The total of 1374 study subjects included 241 outpatients who participated in an H. pylori eradication program (HPE), 679 first-visit outpatients (FVO) at a regional cancer hospital, and 454 local residents who received a health checkup examination (HCE).Results The frequency of the TNF-A -308A allele was only 1.3% of 480 chromosomes in the HPE group, so the FVO and HCE groups were not genotyped for that polymorphism. The genotype frequency of TNF-A C-857T was 69.2% CC, 27.7% CT, and 3.1% TT; that of TNF-A T-1031C was 69.4% TT, 28.1% TC, and 2.5% CC; and that of TNF-B A252G was 36.8% AA, 48.2% AG, and 15.0% GG. TNF-A -857T was tightly linked to TNF-A -1031T and TNF-B 252A. No significant associations between H. pylori seropositivity and polymorphisms of TNF-A C-857T and TNF-B A252G were observed. However, a reduced odds ratio adjusted for sex, age, and recruitment source was observed for TNF-A -1031CC (0.43; 95% confidence interval, 0.20–0.91) relative to TNF-A -1031TT. Subjects with TNF-A -857CC and -1031CC showed the lowest seropositivity (38.2% of 34 participants), while those with TNF-A -857TT and -1031TT showed the highest (66.7% of 42 participants).Conclusions This study suggests that the possibly high expression genotype of TNF-A may increase susceptibility to persistent H. pylori infection. 相似文献
963.
Subjective and functional results after total gastrectomy: prospective study for longterm comparison of reconstruction procedures 总被引:7,自引:0,他引:7
Shinya Adachi Satoshi Inagawa Tsuyoshi Enomoto Eiji Shinozaki Tatsuya Oda Toru Kawamoto 《Gastric cancer》2003,6(1):0024-0029
Background:
Many reconstruction procedures have been developed in efforts to resolve patients' complaints after total gastrectomy. However,
there have been few reports of longterm comparisons between reconstruction procedures, especially with regard to the prevention
of duodenal food passage. This study was undertaken to compare the longterm subjective and functional results among Roux-en-Y
esophagojejunostomy (R-Y), R-Y with pouch (P-Y), and jejunal interposition with pouch (P-I) after total gastrectomy.
Methods:
Consecutive patients requiring curative total gastrectomy were enrolled in this prospective study by the envelope method.
Results:
Hospital stay was longer following a P-I than an R-Y or a P-Y. Over 50% of R-Y patients complained of heartburn, and 20%
of R-Y patients showed dumping syndrome throughout the postoperative period, with this rate being significantly different
from rates in the other two groups. P-Y patients complained of early satiety in the late postoperative period, while P-I patients
complained of early satiety in the early postoperative period. The nutritional index in P-I patients was higher than those
in patients with the other two procedures. Gastrointestinal and hepatobiliary dual scintigraphy (GHDS) showed that the rate
of bile reflux with an R-Y was relatively high after surgery. Food reflux with a P-Y was increased (9.4% to 11.1%), but with
a P-I food reflux was decreased at 3 years after surgery (13.3% to 9.9%). Patients with a P-Y had a faster recovery of body,
weight in the early postoperative period; however, at 5 years after operation, body weight recovery with a P-I was greatest.
Conclusion:
Reconstruction should be performed with pouch formation after total gastrectomy with curative intent.
Received: March 7, 2002 / Accepted: September 26, 2002
Acknowledgments This study was partly supported by the University of Tsukuba Research Project.
Offprint requests to: S. Adachi 相似文献
964.
Loss of expression of DNA repair enzymes MGMT,hMLH1, and hMSH2 during tumor progression in gastric cancer 总被引:11,自引:0,他引:11
Yoshihiko Kitajima Kohji Miyazaki Shiroh Matsukura Masayuki Tanaka Mutsuo Sekiguchi 《Gastric cancer》2003,6(2):86-95
BACKGROUND: Disorders of the DNA repair system that protects against alkylating mutagens are known to play an important role in carcinogenesis. METHODS: We investigated the expression of the DNA repair enzyme that protects against alkylating mutagens, O(6)-methylguanine DNA methyltransferase (MGMT), and the mismatch repair (MMR) enzymes, hMLH1 and hMSH2, in 135 gastric cancer specimens by immunohistochemical means. RESULTS: The immunoreactivity of MGMT and MMR proteins correlated significantly with several clinicopathologic factors. The survival curve in 116 patients showed that a loss of MGMT or hMLH1, but not of hMSH2, correlated with a poor prognosis. Combined evaluation of MGMT and hMLH1 revealed that the survival of patients with negative status for both MGMT and hMLH1 was shortest. However, this significant association between patient survival and MGMT or hMLH1 expression disappeared when early and advanced cancers were separately analyzed, indicating that synchronous losses of MGMT and hMLH1 increase during tumor progression and stage. Further evaluation according to histologic type revealed that loss of MGMT, hMLH1, and hMSH2 expression significantly differed between early and advanced cancer in differentiated-type cancers. In contrast, in undifferentiated-type cancer, loss of MGMT and MMR expression was frequently found even in intramucosal (m) cancer, and no significant difference was found in loss of hMLH1 and hMSH2 between early and advanced cancer. CONCLUSION: These findings demonstrate that the reduced expression of MGMT, hMLH1, and hMSH2 in differentiated-type cancer may play an important role during tumor progression between the early and advanced stage. On the other hand, in undifferentiated-type cancer, loss of MGMT and the MMR proteins appears to be an important event at carcinogenesis or at an earlier step of tumor progression. 相似文献
965.
966.
Yu Xiao Ye Zhangqun Yang Weimin Hu Zhiquan Wang Shaogang Zeng Xiaoyong Zhang Huiping Zeng Lingqi Shang Xuejun Yang Yi 《中德临床肿瘤学杂志》2003,2(1):34-35
Objective To investigate the indications, operation techniques and clinical effects of a modified technique of Indiana pouch.
Methods A modified technique of Indiana pouch was performed on 5 patients following radical cystectomy.
Results 5 cases showed satisfactory therapeutic effects with of follow-up range of 6 to 30 months. All patients were continent day
and night with easy catherization. The number of micturations was 5 to 6 times in the daytime and 1 to 3 times in the nighttime.
Cystography of 4 cases showed that pouches were spheroidic and volumes were between 400 to 500 ml.
Conclusion The advantages of the modified Indiana pouch are as follows: easy manipulation; low tension and high volume in pouches; no
reflux; satisfactory urinary continence and few complications. Therefore, it is worthy of clinical popularization. 相似文献
967.
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. 总被引:9,自引:0,他引:9
Stephanie Geisler Anne-Lise B?rresen-Dale Hilde Johnsen Turid Aas Jürgen Geisler Lars Andreas Akslen Gun Anker Per Eystein L?nning 《Clinical cancer research》2003,9(15):5582-5588
PURPOSE: Recent studies have found an association between certain TP53 mutations and resistance to anthracycline-based primary medical therapy in breast cancer. The purpose of this study was to investigate whether TP53 mutational status also might influence the response to a non-anthracycline-containing regimen in primary breast cancer. EXPERIMENTAL DESIGN: Thirty-five patients with locally advanced breast cancer were investigated for TP53 mutations before receiving combination chemotherapy with 5-fluorouracil (1000 mg/m(2) on days 1 and 2) and mitomycin (6 mg/m(2) on day 2), administered every 3 weeks for 2-10 cycles in the neoadjuvant setting. RESULTS: Mutations in the TP53 gene, in particular those affecting loop domains L2 or L3 of the p53 protein, were associated with lack of response to chemotherapy (i.e., increase in the diameter product of tumor lesion by >/=25%; P = 0.177 for all mutations and P = 0.006 for those affecting L2/L3 domains, respectively). No statistically significant correlation between TP53 LOH and response to therapy was seen. CONCLUSION: This study revealed a significant association between lack of response to 5-fluorouracil and mitomycin and mutations affecting the L2/L3 domains of the p53 protein. Together with our previous finding that such mutations predict resistance to weekly doxorubicin, our data suggest that mutations affecting this particular domain of the p53 protein may cause resistance to several different cytotoxic compounds applied in breast cancer treatment. 相似文献
968.
逆行肝切除治疗难切性肝癌244例报道 总被引:3,自引:0,他引:3
目的 逆行肝切除是治疗难切性肝癌的有效方法 ,本文报道了 2 44例临床经验。方法 常规肝切除方法切除困难的 2 44例巨大、显露困难或下腔静脉受累的肝癌采用逆行切肝法结合血管外科技术予以切除 (A组 ) ,同期临床特征类似的 31例肝癌采用常规切肝法切除 ,作为对照 (B组 )。结果 两组均无手术死亡 ,A组与B组相比 ,术中出血量较少 ( 12 90± 998ml比 2 2 86± 136 3ml)、术后胸水发生率 ( 2 6 /2 44比 10 /31)、腹水发生率 ( 72 /2 44比 19/31)、中度到重度黄疸率 ( 14 /2 44比 5 /31)、手术区积液率 ( 17/2 44比 7/31)、膈下感染率 ( 3/2 44比 1/31)、胆漏发生率 ( 2 /2 44比 1/31)、切口感染率 ( 3/2 44比 1/31)以及ALT恢复时间 ( 13.8± 5 .1天比 18.9± 8.9天 )均较低 ,差别具有统计学意义 (P <0 .0 1)。结论 对于难切性肝癌而言 ,逆行肝切除是安全有效的手术方法。 相似文献
969.
目的 探讨并总结包括腔静脉旁部肝尾叶切除的方法和经验。方法 分别采用右后途径和左侧途径行右尾叶和全尾叶切除;前者附加部分右后叶切除,后者可为单独全尾叶切除或附加左外叶或左半肝切除。结果 成功施行包括腔静脉旁部的肝尾叶切除13例,其中右尾叶切除7例,全尾叶切除6例;全组无手术死亡,术中、术后均无严重病发症发生;术后平均失血量为896.15ml,平均肝门阻断时间为25.40min,术后平均住院12.38天。结论 虽然解剖关系复杂,切除包括腔静脉旁部的肝尾叶安全可行。 相似文献
970.
目的 探讨肝切除治疗原发性肝癌自发性破裂(简称肝癌破裂)的作用。方法 分析我院1973年以来采用肝切除术治疗肝癌破裂12例的临床资料。结果 本组男10例,女2例。平均年龄42(22—65)岁。11例为急症肝切除术,1例为2期肝切除,包括肝左外叶切除6例,左内叶切除1例,左半肝切除1例,右肝部分切除2例,肿瘤局部切除2例。本组中Child-Paugh肝功能分级A组的11例中无死亡;B组者1例术后死于肝衰,手术死亡率为8.3%。术后生存的1例均获随访,平均生存时间为16.5个月,1,3,5年生存率分别为72.7,18.2%,9.1%。其中1例已无瘤生存25年9个月。结论 肝切除是治疗肝癌破裂的最好方法,当有可能时应争取施行。肝切除治疗肝癌破裂可能使患者获行长时间生存。 相似文献